Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Cancer tumor anatomy influences the benefits of chemotherapy for patients with early-stage breast cancer.

2.

Aspirin Fails to Boost Survival in Colorectal Cancer Trial

3.

According to a study, breast cancer cells work together to physically breach barriers and proliferate.

4.

FDA OKs Subcutaneous Daratumumab Plus VRd for Myeloma

5.

The Kansas Cancer Center awarded two Indian American doctors professorships.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot